


What is claimed is:

1. A compound of formula (I):



wherein

- R^1 is -lower alkyl, -CH₂-aryl, -cycloalkyl, -(CH₂)₃-OC(=O)CH₃, -lower alcohol, -lower alkyl-R¹⁰, -CH₂COOH, or -CH₂CH₂OCH₂CH₃;
- R^2 is -lower alkyl, -CH₂-aryl, -lower alcohol, -CH₂C(=O)NH₂, or -lower alkyl-R¹⁰, wherein at least one of R^1 or R^2 is -CH₃;
- R^3 is -COOH, -lower alkyl-COOH, -lower alcohol, -CH₂OCH₃, -CH₂NH₂, -CH₂NHSO₂R¹¹, -C(=O)R¹², -CNHCH₂CH₂-R¹², -C(=NH)-R¹², -(CH₂)_nNHC(=O)R¹³, -(CH₂)_mC(=O)N(R¹⁵)(R¹⁶), -C(=NH)-R¹⁷, or -(CH₂)_n-R¹⁸;
- R^4 is -H, -lower alkoxy, -O-C(R⁷R⁸)C(=O)R¹⁹, -halo, -SCH₃, -C=CHC(=O)-R¹⁰, -CH₂CH₂C(=O)-R¹⁰, -O-lower alcohol, -OCH₂CH(OH)CH₂N=N[±]N[±], -OCH₂CH₂OCH₂CH₂Cl, -NHC(=O)CH₂-R¹⁰, -NHC(=O)CH₂-lower alkyl, -O(CH₂)_n-cycloalkyl,

-O-lower alkene, or a 5 membered unsaturated heterocyclic ring containing one hetero atom which is S or O;

R⁵ and R⁶ are each independently -H, -halo or -lower alkoxy;

R⁷ and R⁸ are each independently -H or -CH₃,

R¹⁰ is a 5 or 6 membered saturated heterocyclyl containing 1 or 2 heteroatoms, wherein each hetero atom is selected from N and O, and the group is bound to the remainder of the molecule at a ring N;

R¹¹ is -CF₃, -lower alkyl, -CH₂Cl, -CH₂CF₃, or -R¹²;

R¹² is a 5 or 6 membered saturated substituted or unsubstituted heterocyclic ring containing one hetero atom which is selected from N, O, and S wherein the substituted ring is the heterocyclic ring substituted with -OH or -phenyl;

R¹³ is -lower alkyl, -lower alkoxy, or -(CH₂)_nR¹⁴;

R¹⁴ is a 5 or 6 membered saturated or unsaturated heterocyclic ring containing one or two hetero atoms which are selected from N and O;


R¹⁵ is -H or -CH₃;

R¹⁶ is -H, -lower alkyl, -C≡N, -OH, -lower alkoxy, or -CH₂COOCH₂CH₃;

R¹⁷ is -lower alkoxy -NH₂ or -N-lower alkyl;

R¹⁸ is a saturated or unsaturated 5 membered substituted or unsubstituted heterocyclic ring containing from 1 to 4 hetero atoms wherein the hetero atoms are selected from N, O and S, wherein the substituted ring is the heterocyclic ring which is substituted at one or two ring carbons with =O, or substituted at a ring N with -lower alcohol or -lower alkyl;

R¹⁹ is -OH, -NHCH(CH₃)₂,
-N(CH₃)CH₂-aryl, -N(CH₃)-lower alkyl,



or 5 or 6 membered saturated substituted or

an unsubstituted heterocyclyl containing 1 or 2 heteroatoms wherein each heteroatom is independently selected from N, O and S, wherein said substituted heterocyclyl is the heterocyclyl substituted with lower alkyl;

m is 0, 1 or 2;

n is 0 or 1;

and pharmaceutically acceptable salts and esters thereof.

2. The compound according to claim 1, wherein R^4 is
-O-lower alkyl, $-O-C(R^7R^8)C(=O)R^{19}$,
-halo, $-SCH_3$, $-C=CHC(=O)-R^{10}$,
 $-CH_2CH_2C(=O)-R^{10}$,
-O-lower alcohol, $-OCH_2CH(OH)CH_2N=N^{\pm}N^{\mp}$,
 $-OCH_2CH_2OCH_2CH_2Cl$, $-NHC(=O)CH_2-R^{10}$,
 $-NHC(=O)CH_2$ -lower alkyl, $-O(CH_2)_n$ -cycloalkyl,
-O-lower alkene, or a 5 membered unsaturated heterocyclic ring containing one heteroatom which is S or O.

3. The compound according to claim 1, wherein R^4 , R^5 and R^6 are each $-H$, and R^1 and R^2 are each $-CH_3$.

4. The compound according to claim 1, wherein R^4 , R^5 and R^6 are each $-H$, and R^3 is $-COOH$.

5. The compound according to claim 1, wherein the compound is selected from:

2-[6,7-Dimethoxy-1-(3-methoxy-benzoyl)-isoquinolin-4-yl]-acetamide
(Example 8);

3-[1-(3-Isopropoxy-benzoyl)-6,7-dimethoxy-isoquinolin-4-yl]-propionamid
(Example 11);

(4-Aminomethyl-6,7-dimethoxy-isoquinolin-1-yl)-(3-isopropoxy-phenyl)-
methanone (Example 13);

2-[1-(3-Isopropoxy-benzoyl)-6,7-dimethoxy-isoquinolin-4-yl]-acetamide
(Example 25);

(4-Aminomethyl-6,7-dimethoxy-isoquinolin-1-yl)-(2-fluoro-5-methoxy-phenyl)-
methanone (Example 27);

1-(2,6-Difluoro-benzoyl)-6,7-dimethoxy-isoquinoline-4-carboxylic acid
(Example 33);

N-[1-(2,6-Difluoro-benzoyl)-6,7-dimethoxy-isoquinolin-4-ylmethyl]-C,C,C-
trifluoro-methanesulfonamide (Example 34);

6,7-Dimethoxy-1-[3-(3-oxo-3-pyrrolidin-1-yl-propenyl)-benzoyl]-isoquinoline-4-
carboxylic acid (Example 35);

6,7-Dimethoxy-1-{3-[(1-phenyl-ethylcarbamoyl)-methoxy]-benzoyl}-
isoquinoline-4-carboxylic acid; compound with trifluoro-acetic acid (Example 39);

6,7-Dimethoxy-1-{3-[(1-phenyl-ethylcarbamoyl)-methoxy]-benzoyl}-
isoquinoline-4-carboxylic acid; compound with trifluoro-acetic acid (Example 42);

1-[3-(1-Isopropylcarbamoyl-1-methyl-ethoxy)-benzoyl]-6,7-dimethoxy-
isoquinoline-4-carboxylic acid; compound with trifluoro-acetic acid (Example 47);

1-(3-Furan-2-yl-benzoyl)-6,7-dimethoxy-isoquinoline-4-carboxylic acid;
compound with trifluoro-acetic acid (Example 49);

6,7-Dimethoxy-1-(3-thiophen-3-yl-benzoyl)-isoquinoline-4-carboxylic acid;
compound with trifluoro-acetic acid (Example 50);

(2-Fluoro-5-isopropoxy-phenyl)-[4-(2-hydroxy-ethyl)-6,7-dimethoxy-isoquinolin-1-yl]-methanone (Example 53);

7-Benzyloxy-6-methoxy-1-(3-methoxy-benzoyl)-isoquinoline-4-carboxylic acid
(Example 62);

7-(2-Hydroxy-ethoxy)-6-methoxy-1-(3-methoxy-benzoyl)-isoquinoline-4-
carboxylic acid (Example 64);

7-Carbamoylmethoxy-6-methoxy-1-(3-methoxy-benzoyl)-isoquinoline-4-
carboxylic acid (Example 65);

6-Methoxy-1-(3-methoxy-benzoyl)-7-(2-pyrrolidin-1-yl-ethoxy)-isoquinoline-4-
carboxylic acid hydrochloride (Example 66);

6-Benzyloxy-7-methoxy-1-(3-methoxy-benzoyl)-isoquinoline-4-carboxylic acid
(Example 67);

6-Cyclopentyloxy-7-methoxy-1-(3-methoxy-benzoyl)-isoquinoline-4-carboxylic
acid (Example 69);

6-(3-Acetoxy-propoxy)-7-methoxy-1-(3-methoxy-benzoyl)-isoquinoline-4-
carboxylic acid (Example 70);

6-(3-Hydroxy-propoxy)-1-(3-isopropoxy-benzoyl)-7-methoxy-isoquinoline-4-carboxylic acid; compound with trifluoroacetic acid (Example 71);

6-Carboxymethoxy-1-(3-isopropoxy-benzoyl)-7-methoxy-isoquinoline-4-carboxylic acid (Example 73);

6-(3-Acetoxy-propoxy)-1-(3-ethoxy-benzoyl)-7-methoxy-isoquinoline-4-carboxylic acid (Example 74);

1-(3-Ethoxy-benzoyl)-6-(2-ethoxy-ethoxy)-7-methoxy-isoquinoline-4-carboxylic acid (Example 76);

1-(3-Ethoxy-benzoyl)-6-(2-hydroxy-ethoxy)-7-methoxy-isoquinoline-4-carboxylic acid (Example 77);

6,7-Dimethoxy-1-(3-methylsulfanyl-benzoyl)-isoquinoline-4-carboxylic acid; compound with trifluoroacetic acid (Example 80);

1-(3-Ethoxy-benzoyl)-6,7-dimethoxy-isoquinoline-4-carboximidic acid ethyl ester, hydrochloride salt (Example 87A);

1-(3-Ethoxy-benzoyl)-6,7-dimethoxy-isoquinoline-4-carboxylic acid amide, hydrochloride salt (Example 87B);

1-(3-Ethoxy-benzoyl)-6,7-dimethoxy-isoquinoline-4-carboxamidine, trifluoroacetic acid salt (Example 88);

(3-Ethoxy-phenyl)-[4-(imino-morpholin-4-yl-methyl)-6,7-dimethoxy-isoquinolin-1-yl]-methanone, trifluoroacetic acid salt (Example 90);

1-(3-Ethoxy-benzoyl)-6,7-dimethoxy-N,N-dimethyl-isoquinoline-4-carboxamidine, trifluoroacetic acid salt (Example 91);

1-(3-Ethoxy-benzoyl)-6,7-dimethoxy-N,N-dimethyl-isoquinoline-4-carboxamidine, trifluoroacetic acid salt (Example 92);

rac-[3-(3-Azido-2-hydroxy-propoxy)-phenyl]-[6,7-dimethoxy-4-(1H-tetrazol-5-yl)-isoquinolin-1-yl]-methanone, trifluoroacetic acid salt (Example 94);

(3-Cyclopentyloxy-4-methoxy-phenyl)-[6,7-dimethoxy-4-(1H-tetrazol-5-yl)-isoquinolin-1-yl]-methanone, trifluoroacetic acid salt (Example 95);

(3-Allyloxy-phenyl)-[6,7-dimethoxy-4-(1H-tetrazol-5-yl)-isoquinolin-1-yl]-methanone, trifluoroacetic acid salt (Example 97);

(3-But-2-enyloxy-phenyl)-[6,7-dimethoxy-4-(1H-tetrazol-5-yl)-isoquinolin-1-yl]-methanone, trifluoroacetic acid salt (Example 98);

(3-Cyclopentyloxy-phenyl)-[6,7-dimethoxy-4-(1H-tetrazol-5-yl)-isoquinolin-1-yl]-methanone, trifluoroacetic acid salt (Example 99);

(3-Cyclopropylmethoxy-phenyl)-[6,7-dimethoxy-4-(1H-tetrazol-5-yl)-isoquinolin-1-yl]-methanone, trifluoroacetic acid salt (Example 100);

(3-Cycloheptyloxy-phenyl)-[6,7-dimethoxy-4-(1H-tetrazol-5-yl)-isoquinolin-1-yl]-methanone, trifluoroacetic acid salt (Example 101);

1-(3-hydroxyethoxy-benzoyl)-6,7-dimethoxy-isoquinoline-4-carboxylic acid (Example 102);

1-{3-[2-(2-Chloro-ethoxy)-ethoxy]-benzoyl}-6,7-dimethoxy-isoquinoline-4-carboxylic acid, trifluoroacetic acid salt (Example 103);

1-(3,5-Dimethoxy-benzoyl)-6,7-dimethoxy-isoquinoline-4-carboxylic acid, trifluoroacetic acid salt (Example 104);

6,7-Dimethoxy-1-(3-methoxy-benzoyl)-isoquinoline-4-carboxylic acid (2-morpholin-4-yl-ethyl)-amide (Example 106);

6,7-Dimethoxy-1-(3-methoxy-benzoyl)-isoquinoline-4-carboxylic acid (2-cyano-ethyl)-amide (Example 107);

6,7-Dimethoxy-1-(3-methoxy-benzoyl)-isoquinoline-4-carboxylic acid hydroxyamide (Example 108);

6,7-Dimethoxy-1-(3-methoxy-benzoyl)-isoquinoline-4-carboxylic acid methoxyamide (Example 109);

6,7-Dimethoxy-1-(3-methoxy-benzoyl)-isoquinoline-4-carboxylic acid methoxymethyl-amide (Example 110);

(4-Hydroxymethyl-6,7-dimethoxy-isoquinolin-1-yl)-(3-isopropoxy-phenyl)-methanone (Example 111);

6,7-Dimethoxy-1-(3-methoxy-5-methyl-benzoyl)-isoquinoline-4-carboxylic acid (Example 112);

[4-(4-Hydroxy-4-phenyl-piperidine-1-carbonyl)-6,7-dimethoxy-isoquinolin-1-yl]-(3-methoxy-phenyl)-methanone (Example 113);

{[6,7-Dimethoxy-1-(3-methoxy-benzoyl)-isoquinoline-4-carbonyl]-amino}-acetic acid ethyl ester (Example 114);

[4-(4-Hydroxy-piperidine-1-carbonyl)-6,7-dimethoxy-isoquinolin-1-yl]-(3-methoxy-phenyl)-methanone (Example 115);

6,7-Dimethoxy-1-(3-methoxy-benzoyl)-isoquinoline-4-carboxylic acid amide (Example 117);

(4-Hydroxymethyl-6,7-dimethoxy-isoquinolin-1-yl)-(3-methoxy-phenyl)-methanone (Example 118);


(6,7-Dimethoxy-4-methoxymethyl-isoquinolin-1-yl)-(3-methoxy-phenyl)-methanone (Example 119);

6,7-Dimethoxy-1-[3-(2-morpholin-4-yl-acetylamino)-benzoyl]-isoquinoline-4-carboxylic acid; compound with trifluoro-acetic acid (Example 120);

6,7-Dimethoxy-1-[3-(2-pyrrolidin-1-yl-acetylamino)-benzoyl]-isoquinoline-4-carboxylic acid; compound with trifluoro-acetic acid (Example 121); and

1-(3-Butyrylamino-benzoyl)-6,7-dimethoxy-isoquinoline-4-carboxylic acid (Example 122).

6. A compound of formula (I),



wherein

R^1 and R^2 are each independently -lower alkyl or -lower alkyl- R^{10} , wherein at least one of R^1 or R^2 is $-CH_3$;

R^3 is $-COOH$, -lower alkyl- $COOH$, $-(CH_2)_nNHC(=O)R^{13}$, $-CH_2NHSO_2R^{11}$, or $-(CH_2)_n-R^{18}$;

R^4 is -lower alkoxy or $-OC(R^7R^8)C(=O)R^{19}$;

R^5 and R^6 are each independently $-H$ or -halo;

R^7 and R^8 are each independently $-H$ or $-CH_3$,

R^{10} is a 5 or 6 membered saturated heterocyclyl containing 1 or 2 heteroatoms, wherein each hetero atom is selected from N and O, and the group is bound to the remainder of the molecule at a ring N;

R^{11} is $-CF_3$, -lower alkyl, $-CH_2Cl$, $-CH_2CF_3$, or $-R^{12}$;


R^{12} is a 5 or 6 membered saturated substituted or unsubstituted heterocyclic ring containing one hetero atom which is selected from N, O, and S wherein the substituted ring is the heterocyclic ring substituted with $-OH$ or -phenyl;

R^{13} is -lower alkyl, -lower alkoxy, or $-(CH_2)_nR^{14}$;

R^{14} is a 5 or 6 membered saturated or unsaturated heterocyclic ring containing one or two hetero atoms which are selected from N and O;

R¹⁸ is a saturated or unsaturated 5 membered substituted or unsubstituted heterocyclic ring containing from 1 to 4 hetero atoms wherein the hetero atoms are selected from N, O and S, wherein the substituted ring is the heterocyclic ring which is substituted at one or two ring carbons with =O, or substituted at a ring N with -lower alcohol or -lower alkyl;

R¹⁹ is -OH, -NHCH(CH₃)₂,
-N(CH₃)CH₂-aryl, -N(CH₃)-lower alkyl,



or 5 or 6 membered saturated substituted or
an unsubstituted heterocyclyl containing 1 or 2 heteroatoms wherein each
heteroatom is independently selected from N, O and S, wherein said substituted
heterocyclyl is the heterocyclyl substituted with lower alkyl;

m is 0, 1 or 2;

n is 0 or 1;

and pharmaceutically acceptable salts and esters thereof.

7. The compound according to claim 6, wherein R⁷ and R⁸ are each -CH₃.

8. The compound according to claim 6, wherein R¹⁰ is -CH₂CH₂-
morpholinyl and the morpholinyl is bound at a ring N.

9. The compound according to claim 6, wherein R¹¹ is -CF₃.

10. The compound according to claim 6, wherein R¹⁹ is -NHCH(CH₃)₂.

11. The compound according to claim 6, wherein R³ is -(CH₂)_nNHC(=O)R¹³,
and n is 1.

12. The compound according to claim 6, wherein R^3 is $-(CH_2)_nNHC(=O)R^{13}$, and R^{13} is $-CH_3$.

13. The compound according to claim 6, wherein R^3 is $-(CH_2)_n-R^{18}$ and R^{18} is an unsaturated 5 membered substituted or unsubstituted heterocyclic ring containing from 2 to 4 hetero atoms which are each N, wherein the substituted ring is the heterocyclic ring which is substituted at a ring N with $-lower alkyl$ or $-lower alcohol$, and n is 0.

14. The compound according to claim 13, wherein R^{18} is tetrazole or substituted tetrazole.

15. The compound according to claim 6, wherein the compound is selected from

1-(2,6-Difluoro-3-isopropoxy-benzoyl)-6,7-dimethoxy-isoquinoline-4-carboxylic acid; compound with trifluoro-acetic acid;

1-(3-sec-Butoxy-benzoyl)-6,7-dimethoxy-isoquinoline-4-carboxylic acid; compound with trifluoro-acetic acid;

1-(3-Isopropoxy-benzoyl)-6,7-dimethoxy-isoquinoline-4-carboxylic acid;

N-[1-(3-Isopropoxy-benzoyl)-6,7-dimethoxy-isoquinolin-4-ylmethyl]-acetamide;

1-[3-(1-Isopropylcarbamoyl-1-methyl-ethoxy)-benzoyl]-6,7-dimethoxy-isoquinoline-4-carboxylic acid; compound with trifluoro-acetic acid;

C,C,C-Trifluoro-N-[1-(2-fluoro-5-methoxy-benzoyl)-6,7-dimethoxy-isoquinolin-4-ylmethyl]-methanesulfonamide;

6,7-Dimethoxy-1-(3-methoxy-benzoyl)-isoquinoline-4-carboxylic acid;

[6,7-Dimethoxy-4-(1H-tetrazol-5-yl)-isoquinolin-1-yl]-(3-ethoxy-phenyl)-methanone; compound, trifluoroacetic acid salt;

2-[1-(2-Fluoro-5-isopropoxy-benzoyl)-6,7-dimethoxy-isoquinolin-4-yl]-4-methyl-pentanoic acid; compound with trifluoro-acetic acid;

N-[1-(3-Isopropoxy-benzoyl)-6,7-dimethoxy-isoquinolin-4-ylmethyl]-nicotinamide;

[6,7-Dimethoxy-1-(3-methoxy-benzoyl)-isoquinolin-4-yl]-acetic acid;

1-(3-Butoxy-benzoyl)-6,7-dimethoxy-isoquinoline-4-carboxylic acid;

1-(3-Ethoxy-benzoyl)-7-methoxy-6-(2-morpholin-4-yl-ethoxy)-isoquinoline-4-carboxylic acid hydrochloride (Example 79);

C,C,C-Trifluoro-N-[1-(3-isopropoxy-benzoyl)-6,7-dimethoxy-isoquinolin-4-ylmethyl]-methanesulfonamide (Example 23);

6,7-Dimethoxy-1-[3-(2-oxo-2-pyrrolidin-1-yl-ethoxy)-benzoyl]-isoquinoline-4-carboxylic acid (Example 1);

6,7-Dimethoxy-1-{3-[2-(4-methyl-piperazin-1-yl)-2-oxo-ethoxy]-benzoyl}-isoquinoline-4-carboxylic acid (Example 2);

6,7-Dimethoxy-1-[3-(2-morpholin-4-yl-2-oxo-ethoxy)-benzoyl]-isoquinoline-4-carboxylic acid (Example 3);

1-{3-[(Benzyl-methyl-carbamoyl)-methoxy]-benzoyl}-6,7-dimethoxy-isoquinoline-4-carboxylic acid (Example 4);

1-{3-[2-(4-Benzyl-piperazin-1-yl)-2-oxo-ethoxy]-benzoyl}-6,7-dimethoxy-isoquinoline-4-carboxylic acid (Example 5);

1-(3-Carboxymethoxy-benzoyl)-6,7-dimethoxy-isoquinoline-4-carboxylic acid (Example 6);

N-[1-(3-Isopropoxy-benzoyl)-6,7-dimethoxy-isoquinolin-4-yl]-acetamide (Example 12);

Pyrazine-2-carboxylic acid [1-(3-isopropoxy-benzoyl)-6,7-dimethoxy-isoquinolin-4-ylmethyl]-amide (Example 16);

N-[1-(3-Isopropoxy-benzoyl)-6,7-dimethoxy-isoquinolin-4-ylmethyl]-2-pyridin-3-yl-acetamide (Example 17);

3H-Imidazole-4-carboxylic acid [1-(3-isopropoxy-benzoyl)-6,7-dimethoxy-isoquinolin-4-ylmethyl]-amide (Example 18);

N-[1-(3-Isopropoxy-benzoyl)-6,7-dimethoxy-isoquinolin-4-ylmethyl]-isonicotinamide (Example 19);

Morpholine-4-carboxylic acid [1-(3-isopropoxy-benzoyl)-6,7-dimethoxy-isoquinolin-4-ylmethyl]-amide (Example 20);

N-[1-(3-Isopropoxy-benzoyl)-6,7-dimethoxy-isoquinolin-4-ylmethyl]-methanesulfonamide (Example 21);

Ethanesulfonic acid [1-(3-isopropoxy-benzoyl)-6,7-dimethoxy-isoquinolin-4-ylmethyl]-amide (Example 22);

[1-(3-Isopropoxy-benzoyl)-6,7-dimethoxy-isoquinolin-4-yl]-acetic acid
(Example 24);

1-(2-Fluoro-5-methoxy-benzoyl)-6,7-dimethoxy-isoquinoline-4-carboxylic acid
(Example 26);

N-[1-(2-Fluoro-5-methoxy-benzoyl)-6,7-dimethoxy-isoquinolin-4-ylmethyl]-methanesulfonamide (Example 28);

1-(2-Fluoro-5-isopropoxy-benzoyl)-6,7-dimethoxy-isoquinoline-4-carboxylic acid
(Example 30);

[1-(2-Fluoro-5-isopropoxy-benzoyl)-6,7-dimethoxy-isoquinolin-4-yl]-acetic acid
(Example 31);

2-[1-(2-Fluoro-5-isopropoxy-benzoyl)-6,7-dimethoxy-isoquinolin-4-yl]-propionic acid (Example 32);

6,7-Dimethoxy-1-[3-(3-oxo-3-pyrrolidin-1-yl-propyl)-benzoyl]-isoquinoline-4-carboxylic acid (Example 36);

1-[3-(Isopropylcarbamoyl-methoxy)-benzoyl]-6,7-dimethoxy-isoquinoline-4-carboxylic acid; compound with trifluoro-acetic acid (Example 37);

6,7-Dimethoxy-1-[3-(2-oxo-2-thiomorpholin-4-yl-ethoxy)-benzoyl]-isoquinoline-4-carboxylic acid; compound with trifluoro-acetic acid (Example 38);

1-{3-[(Ethyl-methyl-carbamoyl)-methoxy]-benzoyl}-6,7-dimethoxy-isoquinoline-4-carboxylic acid; compound with trifluoro-acetic acid (Example 40);

6,7-Dimethoxy-1-{3-[2-oxo-2-(4-phenyl-piperazin-1-yl)-ethoxy]-benzoyl}-isoquinoline-4-carboxylic acid; compound with trifluoro-acetic acid (Example 41);

1-(3-Isobutoxy-benzoyl)-6,7-dimethoxy-isoquinoline-4-carboxylic acid; compound with trifluoro-acetic acid (Example 43);

1-[3-(1,1-Dimethyl-2-oxo-2-pyrrolidin-1-yl-ethoxy)-benzoyl]-6,7-dimethoxy-isoquinoline-4-carboxylic acid; compound with trifluoro-acetic acid (Example 45);

1-(3-Butoxy-benzoyl)-6,7-dimethoxy-isoquinoline-4-carboxylic acid (Example 48);

2-[1-(3-Isopropoxy-benzoyl)-6,7-dimethoxy-isoquinolin-4-ylmethyl]-[1,2,4]oxadiazolidine-3,5-dione; compound with trifluoro-acetic acid (Example 51);

3-[1-(3-Isopropoxy-benzoyl)-6,7-dimethoxy-isoquinolin-4-ylmethyl]-thiazolidine-2,4-dione; compound with trifluoro-acetic acid (Example 52);

2-[1-(2-Fluoro-5-isopropoxy-benzoyl)-6,7-dimethoxy-isoquinolin-4-yl]-4-methyl-pentanoic acid; compound with trifluoro-acetic acid (Example 54);

1-(2,6-Difluoro-3-methoxy-benzoyl)-6,7-dimethoxy-isoquinoline-4-carboxylic acid; compound with trifluoro-acetic acid (Example 55);

[6,7-Dimethoxy-4-(1H-tetrazol-5-ylmethyl)-isoquinolin-1-yl]-(2-fluoro-5-methoxy-phenyl)-methanone (Example 57);

7-Butoxy-6-methoxy-1-(3-methoxy-benzoyl)-isoquinoline-4-carboxylic acid
(Example 63);

6-Butoxy-7-methoxy-1-(3-methoxy-benzoyl)-isoquinoline-4-carboxylic acid
(Example 68);

1-(3-Isopropoxy-benzoyl)-7-methoxy-6-(2-pyrrolidin-1-yl-ethoxy)-isoquinoline-4-
carboxylic acid hydrochloride (Example 72);

6-(3-Acetoxy-propoxy)-1-(3-ethoxy-benzoyl)-7-methoxy-isoquinoline-4-
carboxylic acid hydrochloride (Example 75);

1-(3-Ethoxy-benzoyl)-6-isopropoxy-7-methoxy-isoquinoline-4-carboxylic acid
(Example 78);

1-(3-Ethoxy-benzoyl)-7-methoxy-6-(2-morpholin-4-yl-ethoxy)-isoquinoline-4-
carboxylic acid hydrochloride (Example 79);

[1-(3-sec-Butoxy-benzoyl)-6,7-dimethoxy-isoquinolin-4-yl]-acetic acid; 1:1
trifluoro-acetic acid (Example 81);

1-(3-Ethoxy-benzoyl)-6,7-dimethoxy-isoquinoline-4-carboxylic acid
(Example 84);

(3-Ethoxy-phenyl)-{4-[1-(2-hydroxy-ethyl)-1H-tetrazol-5-yl]-6,7-dimethoxy-
isoquinolin-1-yl}-methanone, trifluoroacetic acid salt (Example 85 A);

(3-Ethoxy-phenyl)-{4-[2-(2-hydroxy-ethyl)-1H-tetrazol-5-yl]-6,7-dimethoxy-
isoquinolin-1-yl}-methanone, trifluoroacetic acid salt (Example 85 B);

[6,7-Dimethoxy-4-(1-methyl-1H-tetrazol-5-yl)-isoquinolin-1-yl]-(3-ethoxy-phenyl)-methanone, trifluoroacetic acid salt (Example 86);

[4-(4,5-Dihydro-1H-imidazol-2-yl)-6,7-dimethoxy-isoquinolin-1-yl]-(3-ethoxy-phenyl)-methanone, trifluoroacetic acid salt (Example 89);

[6,7-Dimethoxy-4-(1H-tetrazol-5-yl)-isoquinolin-1-yl]-[3-(2-hydroxy-ethoxy)-phenyl]-methanone, trifluoroacetic acid salt (Example 93);

[6,7-Dimethoxy-4-(1H-tetrazol-5-yl)-isoquinolin-1-yl]-(3-isopropoxy-phenyl)-methanone, trifluoroacetic acid salt (Example 96);

N-[1-(3-sec-Butoxy-benzoyl)-6,7-dimethoxy-isoquinolin-4-ylmethyl]-C,C,C-trifluoro-methanesulfonamide (Example 105);

(6,7-Dimethoxy-4-pyrrolidin-1-ylmethyl-isoquinolin-1-yl)-(3-methoxy-phenyl)-methanone (Example 116);

N-[6,7-Dimethoxy-1-(3-methoxy-benzoyl)-isoquinolin-4-yl]-acetamide, hydrochloride salt (Example 123);

[6,7-Dimethoxy-1-(3-methoxy-benzoyl)-isoquinolin-4-yl]-carbamic acid methyl ester; compound with trifluoro-acetic acid (Example 124);

C-Chloro-N-[1-(3-isopropoxy-benzoyl)-6,7-dimethoxy-isoquinolin-4-ylmethyl]-methanesulfonamide, hydrochloride salt (Example 125);

Thiophene-2-sulfonic acid [1-(3-isopropoxy-benzoyl)-6,7-dimethoxy-isoquinolin-4-ylmethyl]-amide (Example 126); and

2,2,2-Trifluoro-ethanesulfonic acid [1-(3-isopropoxy-benzoyl)-6,7-dimethoxy-isoquinolin-4-ylmethyl]-amide (Example 127).

16. The compound according to claim 15, wherein the compound is selected from

1-(2,6-Difluoro-3-isopropoxy-benzoyl)-6,7-dimethoxy-isoquinoline-4-carboxylic acid; compound with trifluoro-acetic acid;

1-(3-sec-Butoxy-benzoyl)-6,7-dimethoxy-isoquinoline-4-carboxylic acid; compound with trifluoro-acetic acid;

1-(3-Isopropoxy-benzoyl)-6,7-dimethoxy-isoquinoline-4-carboxylic acid;

N-[1-(3-Isopropoxy-benzoyl)-6,7-dimethoxy-isoquinolin-4-ylmethyl]-acetamide;

1-[3-(1-Isopropylcarbamoyl-1-methyl-ethoxy)-benzoyl]-6,7-dimethoxy-isoquinoline-4-carboxylic acid; compound with trifluoro-acetic acid;

C,C,C-Trifluoro-N-[1-(2-fluoro-5-methoxy-benzoyl)-6,7-dimethoxy-isoquinolin-4-ylmethyl]-methanesulfonamide;

6,7-Dimethoxy-1-(3-methoxy-benzoyl)-isoquinoline-4-carboxylic acid;

[6,7-Dimethoxy-4-(1H-tetrazol-5-yl)-isoquinolin-1-yl]-(3-ethoxy-phenyl)-methanone; compound, trifluoroacetic acid salt;

2-[1-(2-Fluoro-5-isopropoxy-benzoyl)-6,7-dimethoxy-isoquinolin-4-yl]-4-methyl-pentanoic acid; compound with trifluoro-acetic acid;

N-[1-(3-Isopropoxy-benzoyl)-6,7-dimethoxy-isoquinolin-4-ylmethyl]-nicotinamide;

[6,7-Dimethoxy-1-(3-methoxy-benzoyl)-isoquinolin-4-yl]-acetic acid; and

1-(3-Butoxy-benzoyl)-6,7-dimethoxy-isoquinoline-4-carboxylic acid

.

17. The compound according to claim 15, wherein the compound is

1-(3-Ethoxy-benzoyl)-7-methoxy-6-(2-morpholin-4-yl-ethoxy)-isoquinoline-4-carboxylic acid hydrochloride.

18. The compound according to claim 15, wherein the compound is

C,C,C-Trifluoro-N-[1-(3-isopropoxy-benzoyl)-6,7-dimethoxy-isoquinolin-4-ylmethyl]-methanesulfonamide.

19. A pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt or ester thereof according to claim 1, and a pharmaceutically acceptable carrier.

20. A pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt or ester thereof according to claim 6, and a pharmaceutically acceptable carrier.

21. A method for the treatment of type II diabetes in a patient in need of such treatment, comprising administering to the patient a compound according to claim 1 in an amount of from about 10 mg to about 1,000 mg per day.

22. A method for the treatment of type II diabetes in a patient in need of such treatment, comprising administering to the patient a compound according to claim 6 in an amount of from about 10 mg to about 1,000 mg per day.